Best Life Sciences Companies in St. Louis, United States
The 88 best Life Sciences companies in St. Louis, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Veran Medical.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in St. Louis
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Veran Medical Provider of diagnosis of lung cancer by soft tissue navigation | $155M | 90 mo ago | Acquired | 126 | — | WordPressMySQLPHP+24 | 195 patents Ultrasound‑guided minimally invasive catheters for ablation monitoring and pulmonary diagnostics | — |
| 2 | Wugen Developer of CAR-T cell therapy for treatingT-cell malignancies 64Talent top 15%Funding top 21%Patents top 26%Moat top 28% All 9 signals ▾Talenttop 15% Fundingtop 21% Patentstop 26% Moattop 28% Innovationtop 30% Techbottom 45% Marketbottom 43% Globalbottom 40% Newsbottom 22% Talent: Analyst team rating 5/5 Funding: Raised $136M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $136M | 10 mo ago | Series C | 81 | — | WordPressMySQLPHP+24 | 41 patents Immunotherapy platforms: memory NK cell expansion, CD3‑engineered immune cells, CARs, bispecific antibodies | 1 job opening |
| 3 | Geneoscopy Developer of non-invasive biomarker tests for colorectal cancer | $114M | 17 mo ago | Series C | 61 | — | WordPressApple iCloud MailGoogle Workspace+24 | 14 patents Non‑invasive stool‑based nucleic‑acid diagnostics for IBD and colorectal cancer detection | 1 internship · 1 launch · 2 partnerships |
| 4 | MediBeacon Innovating fluorescent technology for improved patient care and disease management | $86M | 33 mo ago | Series D | 25 | Richard Dorshow Co-Founder & CSO | — | 333 patents Patents concentrated in health & consumer products | — |
| 5 | EndoStim Developing neurostimulation treatment for drug-refractory gastroesophageal reflux disease (GERD) | $76M | 89 mo ago | Series D | 4 | Virender Sharma Founder | — | 128 patents Implantable electrical stimulation devices for gastrointestinal neuromodulation therapy | — |
| 6 | Veniti Stent system for chronic venous disease | $65M | 117 mo ago | Acqui-Hired | 28 | — | — | 55 patents Advanced vascular stent designs and delivery mechanisms for improved fracture resistance | — |
| 7 | Stereotaxis Surgical robotics company advancing minimally invasive endovascular intervention for improved patient care | $52M | 72 mo ago | Public | 122 122 → 193 (+58%) | — | DrupalPHPSalesforce+29 | 257 patents Magnetically guided robotic catheters for cardiac electrophysiology and remote interventional navigation | 1 launch |
| 8 | CoverCress Developer of sustainable agriculture technology for farm profitability and promoting renewable energy | $48M | 49 mo ago | Acquired | 37 | — | WebflowApple iCloud MailMicrosoft 365+19 | 40 patents Processing low‑glucosinolate, low‑fiber pennycress meals for plant‑protein food ingredients | 1 launch · 1 partnership |
| 9 | Appistry Developer of tools for clinical labs, hospitals to practice genomically enhanced medicine | $44M | 124 mo ago | Deadpooled | 16 | Guerry Semones Co-Founder | — | 21 patents Distributed, fault‑tolerant middleware for request‑process‑task handling in networked computing | — |
| 10 | Cardialen Developer of cardioversion therapy for atrial fibrillation | $28M | 57 mo ago | Acqui-Hired | 8 | — | — | 10 patents Patents concentrated in health & consumer products | — |
| 11 | Immunophotonics Developer of therapeutics for the treatment of interventional immuno-oncology | $28M | 27 mo ago | Series B | 17 | Robert Nordquist Co-Founder | WordPressPleskMySQL+20 | 63 patents Chitosan-derived glycated biopolymers for immune modulation and antiviral therapies | 1 launch |
| 12 | Indalo Therapeutics Developing small molecules targeting RGD-binding integrins to treat fibrotic diseases | $26M | 106 mo ago | Series A | 8 | Peter Ruminski Co-founder | — | — | — |
| 13 | C₂N Diagnostics Developer of diagnostics and therapies for Alzheimer's disease | $25M | 13 mo ago | Series B | 41 | Ilana Fogelman Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+13 | 94 patents Patents concentrated in computing, sensing & instrumentation | — |
| 14 | ISTO Biologics Developer of treatments for cartilage and bone problems | $24M | 130 mo ago | Acquired | 17 | — | HubSpot CMS HubSalesforceHubSpot+18 | — | — |
| 15 | Plastomics Developer of next-generation trait delivery technology for higher-yielding crops and sustainable agriculture 29Funding top 32%Moat top 37%News top 44%Patents top 46% All 8 signals ▾Fundingtop 32% Moattop 37% Newstop 44% Patentstop 46% Innovationtop 50% Talentbottom 49% Marketbottom 33% Globalbottom 33% Funding: Raised $12.7M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 6 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $13M | 7 mo ago | Series B | 23 | Jeffrey Staub Founder and Chief Scientist | — | 6 patents Plastid genetic engineering for plant trait modification and gene silencing | — |
| 16 | Mobius Therapeutics Ophthalmic surgery solutions | $11M | 151 mo ago | Series B | 9 | — | — | — | — |
| 17 | Elira Developer of wearable device for controlling appetite | $11M | 41 mo ago | Series A | 12 | Danika Harrison CEO & President | — | 41 patents Transcutaneous electrical stimulation devices for glucose‑guided weight loss and appetite control | — |
| 18 | Fimbrion Therapeutics Pioneering anti-virulence therapeutics for urinary tract infections and tuberculosis | $10M | 11 mo ago | Funding Raised | 6 | James Janetka Co-Founder | — | — | — |
| 19 | BacterioScan Bacterial screening device for diagnosis and treatment of infectious diseases | $8M | 102 mo ago | Series A | 14 | Dana Marshall Chief Executive Officer and President | — | 14 patents Rapid optical detection and antibiotic susceptibility testing of microbes in fluid samples | — |
| 20 | Acera Surgical Provider of synthetic electrospun scaffolds for regenerative medical applications | $6M | 92 mo ago | Acquired | 98 | — | Apple iCloud MailMicrosoft 365Windows Server+12 | 55 patents Hybrid-scale fiber matrices for advanced tissue engineering and regenerative medical implants | 1 partnership |
| 21 | Senseion Therapeutics Developer of therapeutics for the treatment of metabolic diseases | $6M | 15 mo ago | Funding Raised | — | Rajan Sah Co-Founder | — | — | — |
| 22 | Keystone Bio Developer of biotherapeutics for the treatment of multiple diseases | $5M | 85 mo ago | Series A | 3 | Garth Ehrlich Co-Founder | — | — | — |
| 23 | Mediomics Innovative assay kits and biosensors for research, diagnostics, and therapeutics | $5M | 71 mo ago | Funding Raised | — | Yie Hwa Chang Founder | — | 41 patents Multiplexed, signal‑amplified molecular biosensors for detecting specific biomolecular epitopes | — |
| 24 | Sparo App and smart spirometer for detecting lung health | $4M | 95 mo ago | Acqui-Hired | 4 | Abigail Cohen Co-Founder & Co-CEO | — | 18 patents Home-based spirometry devices with gamified data collection and automated analysis | — |
| 25 | Omniose Developer of polysaccharide conjugate vaccines against bacterial threats | $4M | 32 mo ago | Seed | 7 | Christine Szymanski Co-Founder | — | — | — |
| 26 | Unleash Immuno Oncolytics Developing stroma-targeted oncolytic immunotherapy to unleash the immune response against cancer | $3M | 100 mo ago | Deadpooled | 4 | — | — | 8 patents Engineered oncolytic adenoviral vectors for targeted cancer gene therapy | — |
| 27 | RNAgri Biotechnology company developing RNA production technology | $3M | 98 mo ago | Acqui-Hired | — | Juan Arhancet Founder | — | — | — |
| 28 | NeuroLutions Developer of robotic glove controlled by brain | $2M | 16 mo ago | Series A | 9 | Eric Leuthardt Co-Founder | WordPressApple iCloud MailGoogle Workspace+27 | 70 patents BCI-driven neurorehabilitation and assistive orthotic devices for motor control and pain relief | — |
| 29 | MOgene Provider of comprehensive genomics services for industrial research groups and institutions | $2M | 152 mo ago | Funding Raised | 20 | — | — | 8 patents Engineered methanotrophic and phototrophic microbes for hydrocarbon biosynthesis | — |
| 30 | Capella Imaging Developer of diagnostic imaging agents for cardiac disorders | $2M | 105 mo ago | Funding Raised | — | Gregory Lanza Co-Founder | — | — | — |
| 31 | APT Therapeutics Transforming human apyrase into life-saving medicine for thrombotic diseases | $2M | 14 mo ago | Seed | 2 | — | — | — | — |
| 32 | Traxxsson Developer of protein biomarkers for cancer diagnostics | $2M | 144 mo ago | Seed | — | Robert Puskas Founder and CTO | — | 16 patents Diagnostic assays for cancer using pKa measurement and combinatorial biomarker methods. | — |
| 33 | Kinimmune Developer of immuno-therapeutics for solid tumors | $1M | 17 mo ago | Funding Raised | — | Cory Berkland Co-Founder & CEO | — | — | — |
| 34 | Nawgen Provider of miRNA based research assay kits and CRO services | $1M | 99 mo ago | Funding Raised | — | Xiaowei Wang Founder | — | — | — |
| 35 | KaloCyte Developer of a nanotechnology-based red blood cell substitute | $1M | 13 mo ago | Seed | 8 | Dipanjan Pan Co-Founder | WordPressApple iCloud MailZoho+23 | 28 patents Lipid nanoparticle oxygen carriers for hemorrhagic shock and bio‑synthetic nanoparticle clearance | — |
| 36 | MagBiosense POC device for cardiac disease diagnosis | $1M | 126 mo ago | Funding Raised | 3 | — | — | 2 patents Low‑autofluorescence capture surfaces for fluorescence‑based bioassays | — |
| 37 | OxyBand Advanced transdermal oxygen therapy for wound healing and tissue regeneration | $700K | 195 mo ago | Series A | 4 | Amie Franklin President & CEO | — | 44 patents Advanced wound care technologies: diffusion dressings, gas delivery, and infrared monitoring. | — |
| 38 | Antegrin Therapeutics Small molecule integrin inhibitors for fibrotic diseases | $696K | 128 mo ago | Seed | — | George Capps CEO | — | — | — |
| 39 | Accuronix Small molecule therapeutics for cancer. | $625K | 81 mo ago | Seed | 3 | — | — | — | — |
| 40 | EDIS Drug data integration platform for pharmaceutical strategy development | $504K | 123 mo ago | Deadpooled | 6 | Dan Bemus Co-Founder & Board Member | — | — | — |
| 41 | DOJO LABS Developer of supplements for cognitive health | $500K | 39 mo ago | Deadpooled | 4 | Brian Goldberg Co-Founder | — | — | — |
| 42 | Precision Virologics Developing biologically targeted adenovirus vaccines to treat infectious diseases | $500K | 110 mo ago | Deadpooled | 2 | — | — | — | — |
| 43 | Katalyst Surgical Surgical instruments innovator for anterior, glaucoma, and posterior retina procedures | $340K | 121 mo ago | Acquired | 53 | Gregg Scheller CEO | Wix eCommerceCart FunctionalityWix+14 | 310 patents Ophthalmic surgical tools for retinal membrane peeling and intraocular illumination systems | — |
| 44 | Cicadea Biotech Developer of PCR-based assays | $305K | 14 mo ago | Funding Raised | — | Lucy Burns Founder & CEO | — | — | — |
| 45 | GenAssist Developer of a biomaterial scaffold for muscle regeneration | $295K | 37 mo ago | Funding Raised | 4 | Gabriel Haas Founder and Chief Technology Officer | — | — | — |
| 46 | RadTargX Therapeutics Antibody-based immunomodulators for cancer | $278K | 169 mo ago | Deadpooled | — | Randy Weiss Co-Founder | — | — | — |
| 47 | VirRx Develops cancer gene therapies. | $261K | 202 mo ago | Deadpooled | — | Robert E Sobol CEO | — | — | — |
| 48 | Drug Design Methodologies Provider of drug design methodologies with a focus on ligand refinement software | $226K | 100 mo ago | Funding Raised | — | Chris Ho Owner | — | — | — |
| 49 | Dignity Medical Developer of medical device to assist people with functional urinary incontinence | $100K | 87 mo ago | Deadpooled | 2 | Bert Hensley Chairman & CEO | — | — | — |
Top 12 Life Sciences companies in St. Louis
#1
Series C · St. Louis, Missouri · founded 2018 · 81 employees$135.7Mraised▾
Developer of CAR-T cell therapy for treating T-cell malignancies. The company has developed an allogeneic CAR-T therapy platform for the treatment. Deletion of the T-cell receptor (TCR) enables the use of T-cells from healthy donors without the risk of life-threatening Graft vs. Host Disease (GvHD). It has developed a pipeline for Head & Neck Cancer, Melanoma, and Solid Tumors.
- Aug 2025Series C$115M
- Jul 2021Series B$98.5M
- Apr 2020Series A$37.2M
- 2019Seed—
#2
Series B · St. Louis, Missouri · founded 2016 · 23 employees$12.7Mraised▾
Developer of next-generation trait delivery technology for higher-yielding crops and sustainable agriculture. It offers a platform that places beneficial traits in the chloroplast of plant cells, enhancing crop performance. This approach simplifies product development, improves product effectiveness, and creates new market opportunities. The technology enables crops to better withstand insects, diseases, and weeds, leading to higher yields. By focusing on chloroplast trait introduction, they address challenges like pest resistance, trait outcrossing, and complex trait integration. This platform offers solutions for seed companies, providing a valuable tool to help growers meet the nutritional needs of a growing population. The technology supports sustainable agriculture by reducing the need for chemicals and enhancing crop resilience.
- Oct 2025Series B$5.8M
- Nov 2021Series A$7.1M
- May 2021Series A$3.2M
- Mar 2021Series A$2.4M
#3
Series C · St. Louis, Missouri · founded 2015 · 61 employees$113.9Mraised▾
Developer of non-invasive biomarker tests for colorectal cancer. The flagship assay analyzes stool samples for a panel of disease-associated mRNA biomarkers using a proprietary diagnostic algorithm to detect colorectal cancer. The company plans that its assay will be used to screen patients in need of a more invasive colonoscopy.
- Jan 2025Series C$105M
- Nov 2021Series B$105M
- Nov 2021Conventional Debt—
- Sep 2019Series A$7.9M
#4
Series B · St. Louis, Missouri · founded 2007 · 41 employees$25Mraised▾
Developer of diagnostics and therapies for Alzheimer's disease. The product include PrecivityAD blood test that is intended for use in patients with cognitive impairment and to determine the presence or absence of amyloid plaques in the brain. It also offers bioanalytical services for pharmaceutical and biotechnology companies.
- May 2025Conventional Debt$10M
- Mar 2025Series B$10M
- Oct 2024Grant (prize money)$15M
- Sep 2024Grant (prize money)$7M
#5
Funding Raised · St. Louis, Missouri · founded 2012 · 6 employees$10.3Mraised▾
Pioneering anti-virulence therapeutics for urinary tract infections and tuberculosis. The company focuses on developing novel antibacterial therapies and alternatives to traditional antibiotics. They are dedicated to creating powerful solutions to combat infectious diseases, particularly urinary tract infections and tuberculosis. Their pipeline includes oral antibacterial co-development and antibiotic-sparing approaches. They are committed to pioneering anti-virulence solutions, researching and developing innovative treatments. The company's work has potential social impact by addressing antibiotic resistance. They are involved in drug discovery and development, aiming to provide effective treatments for infectious diseases.
- Jul 2025Grant (prize money)$300K
- May 2025Grant (prize money)$600K
- Feb 2025Grant (prize money)$3M
- Mar 2023Grant (prize money)$600K
#6
Funding Raised · St. Louis, Missouri · founded 2019$6.3Mraised▾
Developer of therapeutics for the treatment of metabolic diseases. The company uses in vivo genetic models reveal SWELL1/LRRC8 Channels to regulate essential metabolic and cardiovascular function. The company product include SN-40X for the treatment of diabetes and its complications, including cardiovascular disease.
- Mar 2025Grant (prize money)$2.3M
- Sep 2023Grant (prize money)$1.3M
- Sep 2021Grant (prize money)$990.9K
- Sep 2020Grant (prize money)$1.4M
#7
Seed · St. Louis, Missouri · founded 2016 · 8 employees$1.1Mraised▾
Developer of a nanotechnology-based red blood cell substitute. It offers ErythroMer an immuno-silent nanoparticle that emulates the surface of an RBC and allows for physiologically relevant gas exchange due to the presence of an embedded molecular shuttle that exhibits context-dependent oxygen binding. The technology is targeted toward patient care in low-resource settings such as battlefields, remote locations, etc. to reduce mortality from trauma-related blood loss.
- May 2025Grant (prize money)$3M
- Feb 2025Grant (prize money)$500K
- Apr 2024Grant (prize money)$2.5M
- Jul 2022Seed—
#8
Seed · St. Louis, Missouri · founded 2001 · 2 employees$1.6Mraised▾
Transforming human apyrase into life-saving medicine for thrombotic diseases. This company focuses on developing therapeutics to address conditions caused by platelet aggregation, a major factor in thrombotic diseases. Their lead product minimizes damage from heart attack without increasing hemorrhage. They are dedicated to innovation in the medical field, aiming to provide solutions for acute lung injury and pulmonary arterial hypertension. Their work has a significant social impact, potentially improving outcomes for patients suffering from life-threatening conditions. They are involved in research and development, seeking to translate scientific discoveries into practical treatments.
- Mar 2025Grant (prize money)$4.7M
- May 2023Grant (prize money)$2.9M
- Jun 2021Grant (prize money)$259.6K
- Sep 2019Grant (prize money)$300K
#9
Series A · St. Louis, Missouri · founded 2007 · 9 employees$2Mraised▾
NeuroLutions is developing devices based on brain-computer interface technology restoring functions in patients disabled due to neurological injury. It is developing a robotic glove that the user can wear it on their hand and a headset.
- Feb 2025Series A$26.5M
- Sep 2022Grant (prize money)$2M
- Jun 2015Seed$1.1M
- Nov 2008Seed$625K
#10
Series D · St. Louis, Missouri · founded 2011 · 25 employees$86.5Mraised▾
Innovating fluorescent technology for improved patient care and disease management. The company specializes in advancing fluorescent tracer agents and transdermal measurement for physiological monitoring. Their technology enables new clinical applications and solutions, focusing on areas like nephrology, gastroenterology, ophthalmology, and surgery. They engineer fluorescent agents designed not to interact with the body, enabling measurement and monitoring of vital organ systems. The company's R&D platform is dedicated to developing innovative systems for disease progression monitoring. They aim to provide clinically practical solutions that reduce healthcare costs while improving the standard of care. Their focus areas include point-of-care assessment of renal function and gastrointestinal permeability, as well as fluorescent agent angiography. The company is committed to quality, concentrating on the integrity of processes and preventive measures. They offer preclinical products and are progressing clinical technologies through trials.
- Aug 2023Series D$16.1M
- Nov 2022Series C$10M
- Jan 2022Series C$8.1M
- Sep 2019Series C$34.3M
#11
Series B · St. Louis, Missouri · founded 2008 · 17 employees$28.1Mraised▾
Developer of therapeutics for the treatment of interventional immuno-oncology. The company is engaged in the development of a proprietary novel drug product for use in an in situ autologous cancer vaccine (inCVAX) for the treatment of metastatic solid tumors. The technology uses proprietary N-dihydro-galacto-chitosan, a carbohydrate polymer, which enhances the antigen uptake, and stimulates immune response when injected in combination with checkpoint inhibitors after laser treatment.
- Feb 2024Conventional Debt$1.5M
- Feb 2023Series B$3.5M
- Apr 2022Series B$21.4M
- Aug 2021Grant (prize money)$2.4M
#12
Funding Raised · St. Louis, Missouri · founded 2020$1.2Mraised▾
Developer of immuno-therapeutics for solid tumors. It offers intratumoral immunostimulants that provide checkpoint inhibition in solid tumors which include KIN-101, KIN-102, and KIN-201.
- Jan 2025Grant (prize money)$381.5K
- Nov 2022Grant (prize money)$400K
- Sep 2022Grant (prize money)$381.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.